Hormone drug may slow Aging-Related diseases in rare condition
NCT ID NCT03312400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether low doses of the hormone drug danazol can slow the shortening of telomeres—the protective caps on DNA—in people with telomere diseases. These conditions can cause bone marrow failure, lung scarring, and liver damage. Eighteen participants took danazol for one year, and researchers measured changes in telomere length, lung function, and liver health. The goal was to see if the drug is safe and can reduce the rate of telomere loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Danazol (a synthetic hormone)
- What this could lead to
- If successful, this could provide a treatment option to slow disease progression in people with telomere-related conditions.
- What could go wrong
- This is a small, early-phase trial with only 18 participants, so results may not apply broadly. Danazol can cause hormonal side effects, and the long-term benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TELOMERE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.